FLT PET in patienten met niet kleincellig long carcinoom behandeld met gefitinib.

Validation of simplified quantitative [18F]FLT PET methods in NSCLC patients treated with gefitinib.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24060

Enrollment

Registered

2012-08-02

Start date

2012-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

[15O]H2O and [18F]FLT PET scan at 3 different timepoints.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient age 18 years or older; 2. Histological diagnosis of NSCLC; 3. Active EGFR-TK mutation; 4. Scheduled for treatment with gefitinib; 5. Tumour diameter > 3cm (to minimize partial volume effects) within the chest; 6. Able to remain supine for 90 minutes in the PET-CT scanner; 7. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients; 2. Metal implants (e.g. pacemakers); 3. Body weight > 100 kg.

Design outcomes

Primary

Measure	Time frame
The study parameters are the results of the simplified measures and the pharmacokinetic modeling of [18F]FLT PET prior to therapy and during treatment with gefitinib.	—

Secondary

Measure	Time frame
Secondary, nonlinear kinetic filtering will be evaluated and perfusion measured with [15O]H2O PET.	—

Contacts

Public ContactO.S. Hoekstra

Box 7057

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)